The US Food and Drug Administration on Wednesday approved Pfizer’s RSV vaccine for older adults, the second such shot approved for the common virus. Earlier in May, the agency approved the world ...

US FDA approves GSK's Arexvy, the world's first respiratory syncytial virus (RSV) vaccine for older adults. Hamid S, Winn A, Parikh R, et al. Seasonality of respiratory syncytial virus—United ...

US FDA approves Pfizer’s RSV vaccine Abrysvo for adults aged 18 to 59 at increased risk for disease. Pfizer Inc. News release. October 22, 2024. Accessed October 23, 2024.

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the ...

Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...

RSV typically causes cold-like symptoms, but is also a leading cause of pneumonia in toddlers and older adults. The CDC estimates 15,000–20,000 annual RSV-associated hospitalizations in the U.S ...

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a welcome win.

Pfizer was the first COVID-19 vaccine to receive emergency approval in December 2020 and Moderna was followed one week later. The first Covid-19 case was reported in the United States on Jan. 20 ...

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease.

Moderna's RSV shot, mRESVIA, was the first non-COVID-19 messenger RNA-based (mRNA) vaccine to be approved in the United States. The shot, the company's second product, is already approved for the ...